These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9105840)

  • 21. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
    Vella S; Floridia M; Dally LG; Tomino C; Fragola V; Weimer LE; Milazzo F; Mazzotta F; Moroni M; Pastore G; Scalise G; Sinicco A; Ortona L; De Rienzo B; Dianzani F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):462-9. PubMed ID: 8757422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
    Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
    Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
    Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
    ;
    AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
    N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
    Spruance SL; Pavia AT; Peterson D; Berry A; Pollard R; Patterson TF; Frank I; Remick SC; Thompson M; MacArthur RD; Morey GE; Ramirez-Ronda CH; Bernstein BM; Sweet DE; Crane L; Peterson EA; Pachucki CT; Green SL; Brand J; Rios A; Dunkle LM; Cross A; Brown MJ; Ingraham P; Gugliotti R; Schindzielorz AH; Smaldone L
    Ann Intern Med; 1994 Mar; 120(5):360-8. PubMed ID: 7905722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
    Kelleher T; Cross A; Dunkle L
    Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.
    Nguyen BY; Yarchoan R; Wyvill KM; Venzon DJ; Pluda JM; Mitsuya H; Broder S
    J Infect Dis; 1995 May; 171(5):1180-9. PubMed ID: 7751692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
    Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.